Pulmonary Edema News and Research

RSS
FDA approves change to prescribing information for Gilead Sciences' Letairis

FDA approves change to prescribing information for Gilead Sciences' Letairis

Positive results from Medtronic CoreValve System study for treatment of aortic valve disease

Positive results from Medtronic CoreValve System study for treatment of aortic valve disease

Patient need to share medication side effects with health care team: Retired family doctor

Patient need to share medication side effects with health care team: Retired family doctor

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

Researchers investigate impact of fungal toxin on birth defects

Researchers investigate impact of fungal toxin on birth defects

FDA approves Gamunex-C for primary immunodeficiency treatment

FDA approves Gamunex-C for primary immunodeficiency treatment

J&JPRD receives FDA Complete Response Letter for tapentadol ER tablets NDA

J&JPRD receives FDA Complete Response Letter for tapentadol ER tablets NDA

PGIC analysis indicates tapentadol ER tablets provide significant improvement in pain intensity

PGIC analysis indicates tapentadol ER tablets provide significant improvement in pain intensity

Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study

Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study

Dose-defining Phase IIa trial of CXL-1020 initiated for treating patients with ADHF

Dose-defining Phase IIa trial of CXL-1020 initiated for treating patients with ADHF

Cardioxyl Pharmaceuticals achieves positive results in first clinical study of CXL-1020 for ADHF

Cardioxyl Pharmaceuticals achieves positive results in first clinical study of CXL-1020 for ADHF

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

St. Jude Medical commences enrollment in LAPTOP-HF study

St. Jude Medical commences enrollment in LAPTOP-HF study

Phase II study results of riociguat for CTEPH and PAH published online

Phase II study results of riociguat for CTEPH and PAH published online

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Human stem cells restore alveolar epithelial tissue after E. coli endotoxin-induced ALI: Researchers

Human stem cells restore alveolar epithelial tissue after E. coli endotoxin-induced ALI: Researchers

High-altitude exposure helps detect early vascular dysfunction

High-altitude exposure helps detect early vascular dysfunction